ALK‐positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long‐term survival of more than seven years with sequential treatment of five ALK‐inhibitors: A case report. Issue 11 (3rd May 2021)

• Record Type: Journal Article
• Authors: Yamamoto, Keisuke; Toyokawa, Gouji; Kozuma, Yuka; Shoji, Fumihiro; Yamazaki, Koji; Takeo, Sadanori
• Is Part Of: Thoracic cancer. Volume 12:Issue 11(2021)
• Page Start: 1761
• Page End: 1764
• Publication Date: 2021-05-03
• Subjects: anaplastic lymphoma kinase -- brain metastases -- lorlatinib -- non‐small cell lung cancer; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.13962
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract: The incidence of central nervous system (CNS) metastases in patients with anaplastic lymphoma kinase ( ALK ) fusion gene‐positive ( ALK+ ) non‐small cell lung cancer (NSCLC) is high, ranging from approximately 20%–70%. Although ALK inhibitors (ALKis) are generally effective for CNS metastases in patients with ALK+ NSCLC, relapse with CNS metastases is frequently observed. A 37‐year‐old woman with a high level of carcinoembryonic antigen was diagnosed with right lung adenocarcinoma (pathological stage IIIA) and underwent right lower lobectomy. Despite the administration of postoperative chemotherapy, her carcinoembryonic antigen (CEA) level remained elevated. Although crizotinib was administered due to the positivity for ALK fusion, brain metastases appeared at 19.0 months after the start of treatment. Treatment with alectinib following crizotinib resulted in the complete disappearance of brain metastases. However, brain metastases relapsed, and meningeal dissemination appeared at 38.3 months after the start of treatment with alectinib. Although ceritinib, brigatinib, and alectinib rechallenge were attempted, the CNS lesions worsened. Lorlatinib was then administered, resulting in the normalization of the CEA level (4.5 ng/ml) 4.1 months after the start of lorlatinib. The brain metastases and meningeal dissemination almost disappeared. The overall time from the start of crizotinib to lorlatinib is 89.5 months at present, and the patient continues to be treated with lorlatinib without relapse. Lorlatinib was effective in this case with brain metastases and meningeal dissemination after resistance to first‐ and second‐generation ALKis. Appropriate sequential treatment with first‐, second‐ and third‐generation ALKis can lead to a long‐term survival in ALK+ patients with brain metastases and meningeal dissemination. Abstract : ALK inhibitors are effective in ALK ‐positive lung cancer, but the acquisition of resistance, metastases and relapses are problems to be urgently solved. Lorlatinib, a third‐generation ALK inhibitor, showed a significant response in an ALK ‐positive lung cancer patient with relapses of brain metastases and meningeal dissemination after acquiring resistance to first‐ and second‐generation ALK inhibitors.